<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">For both NTX and placebo groups in the study by Cook et al., 2017, after 4 and 7 month treatment, the CD4 counts improved than baseline and due to small amounts of numbers, it isn’t possible to make meaningful conclusions (“The pooled effect size for CD4 counts was standard mean difference (SMD)=0.13, 95% CI: -0.48 to 0.73”) [
 <xref ref-type="bibr" rid="CR44">44</xref>]. Edelman et al., 2019 reported that for the XR-NTX group, the estimated mean CD4 was lower than the placebo group at baseline and this difference were not statistically-significant (
 <italic>p</italic> = 0.75) [
 <xref ref-type="bibr" rid="CR45">45</xref>].
</p>
